title: [A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
abstract: The patient was a 59-year-old man who was hospitalized at our department for intestinal obstruction. Contrast enhanced abdominal CT showed a rectosigmoid tumor invading the left pelvic wall and multiple metastatic hepatic tumors. Colonoscopy showed a type-2 cancer in the rectosigmoid region. The patient underwent sigmoid colostomy 3 days after admission. Postoperative upper gastrointestinal endoscopy showed a type 3 cancer in the fornix. From the above findings, the patient was diagnosed with unresectable gastric and rectosigmoid cancers with multiple hepatic metastases, and systemic chemotherapy was initiated. The first line treatment was two courses of S-1, but it was discontinued due to PD. FOLFIRI was begun as the second line treatment. After 5 courses of FOLFIRI, upper gastrointestinal endoscopy showed a marked reduction in tumor size. Twelve courses of FOLFIRI chemotherapy were performed in total. Subsequently, 11 courses of mFOLFOX6 and 1 course of RPMI were performed, but the patient died from carcinomatous peritonitis. However, the gastric lesion had been controlled well after the second line treatment. The findings of the present study suggested that FOLFIRI could be an effective treatment for unresectable multiple advanced cancers of the stomach and colorectal cancer.
authors.affiliation: Dept. of Surgery, Hasuda Hospital.
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Aoyagi
authors.forename: Jun
authors.initials: J
authors.lastname: Kaneko
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ono
authors.forename: Jun
authors.initials: J
authors.lastname: Isogai
authors.forename: Masafumi
authors.initials: M
authors.lastname: Yoshida
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Someno
authors.forename: Eriko
authors.initials: E
authors.lastname: Katsuta
authors.forename: Morihito
authors.initials: M
authors.lastname: Saguchi
authors.forename: Taro
authors.initials: T
authors.lastname: Takahata
authors.forename: Kumi
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Setsuo
authors.initials: S
authors.lastname: Hamada
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
authors.forename: Shizuaki
authors.initials: S
authors.lastname: Maejima
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000628:therapy*; D012811:Sigmoid Neoplasms / Q000473:pathology* / Q000601:surgery; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin